A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

Published 2015 View Full Article

Authors

Keywords

Journal

CRITICAL CARE MEDICINE

Volume 43, Issue 9, Pages 1859-1869

Publisher

Ovid Technologies (Wolters Kluwer Health)

Online

2015-06-24

DOI

10.1097/ccm.0000000000001132

Ask authors/readers for more resources

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

CRITICAL CARE MEDICINE

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Become a Peeref-certified reviewer

Ask a Question. Answer a Question.